(Q38043507)

27 August 2017

title

The promise of mTOR inhibitors in the treatment of colorectal cancer (English)

1 reference

27 August 2017

1 reference

Dae-Dong Kim

1

1 reference

27 August 2017

Cathy Eng

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

16 September 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

published in

1 reference

27 August 2017

volume

21

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1775-1788

1 reference

A genetic model for colorectal tumorigenesis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Differential colorectal carcinogenesis: Molecular basis and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Genetic prognostic and predictive markers in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Hyperactive Ras in developmental disorders and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

mTOR, translation initiation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Targeting mTOR in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Early clinical experience with a novel rapamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Tor signalling in bugs, brain and brawn

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Integration of Growth Factor and Nutrient Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

New insights into mTOR signaling: mTORC2 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

cDNA cloning of a Novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF β-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

TOR controls translation initiation and early G1 progression in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

A complex interplay between Akt, TSC2 and the two mTOR complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Cancer phenomics: RET and PTEN as illustrative models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The hamartomatous polyposis syndromes: a clinical and molecular review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The role of PTEN signaling perturbations in cancer and in targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Targeting the PI3K signaling pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Non-genomic loss of PTEN function in cancer: not in my genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Colorectal cancer: mutations in a signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Perifosine: update on a novel Akt inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Current and future directions in mammalian target of rapamycin inhibitors development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Targeting mTOR with rapamycin: one dose does not fit all

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Expanding the repertoire of RNA interference screens for developing new anticancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

RNAi screening for therapeutic targets in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Combining radiation and molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.721353

10.1517/13543784.2012.721353

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference